Publications and communications of Christine Grignet

Bricmont, N., Benchimol, L., POIRRIER, A.-L., Grignet, C., Seaton, C., Chilvers, M. A., Seghaye, M.-C., Louis, R., Lefèbvre, P., & KEMPENEERS, C. (2020). Nasal Brushing Sampling and Processing using Digital High Speed Ciliary Videomicroscopy - Adaptation for the COVID-19 Pandemic. Journal of Visualized Experiments, (165). doi:10.3791/61949

Grignet, C. (22 February 2018). Comment prévenir le risque biologique en laboratoire ou animalerie de recherche ? [Paper presentation]. Jeudis de la santé au travail, Liège, Belgium.

Humblet, M.-F., Vanderschueren, P., Grignet, C., Cassart, D., Korsak Koulagenko, N., & Saegerman, C. (2017). Observations as a way to assess the compliance of veterinary students with biosecurity procedures. Revue Scientifique et Technique. Office International des Epizooties, 36 (3). doi:10.20506/rst36.3.2712

Grignet, C. (26 January 2016). Travail en laboratoire de niveau de confinement 2 (L2) [Paper presentation]. Biosecurity day - 4ème édition - Faculté de Médecine vétérinaire de l'U.Lg.

Humblet, M.-F., Vanderschueren, P., Grignet, C., Cassart, D., Korsak Koulagenko, N., & Saegerman, C. (May 2014). Observance as a tool to assess the compliance of vet students to biosecurity rules in a veterinary necropsy room and at a slaughterhouse [Poster presentation]. 17th Annual European Biosafety Association Conference, Ghent, Belgium.

Grignet, C. (2013). La protection de l’environnement et les installations classées en Belgique [Paper presentation]. Journées du Groupement National pour la Prévention des Risques Professionnels dans l’Enseignement Supérieur français, Liège, Belgium.

Grignet, C. (2013). La gestion du risque biologique en Belgique [Paper presentation]. Journées du Groupement National pour la Prévention des Risques Professionnels dans l’Enseignement Supérieur français, Liège, Belgium.

Grignet, C. (27 February 2013). Gestion du risque biologique en laboratoires : démarche et enjeux [Paper presentation]. Séminaires de la recherche - Faculté de Médecine vétérinaire ULG.

Grignet, C. (2008). The practical challenges of the Biosafety officer : interacting with the user. In The Biosafety Professional: roles and interactions in a complex network.

Drion, P., Grignet, C., Ectors, F., & Rentier, B. (26 September 2006). Mise en route des animaleries GIGA souris et zébrafish: biosécurité, guide du chercheur et complémentarité avec l'Animalerie Centrale ULG - CHU [Paper presentation]. Séminaires du CBIG - GIGA, CHU, Liège, Belgium.

Drion, P., & Grignet, C. (2006). Implementing BSL II & BSL III activities in an existing facility : the case of the Animal facility of the CHU at University of Liège, Belgium " [Paper presentation]. Colloque Scientifique Tecnilab, Milano, Italy.

Grignet, C., Noël, A., Foidart, J.-M., & Calberg-Bacq, C. M. (2005). Identification of factors important for the success of suicide gene therapy after a comparative study of Varicella zoster and Herpes simplex viral thymidine kinases efficacy on breast cancer cells. Cellular and Molecular Biology, 51 (1), 37-48. doi:10.1170/T596

Masson, V., Devy, L., Grignet, C., Berndt, S., Bajou, K., Blacher, S., Roland, G., Chang, Y., Fong, T., Carmeliet, P., Foidart, J.-M., & Noël, A. (28 October 2002). Mouse Aortic Ring Assay: A New Approach of the Molecular Genetics of Angiogenesis. Biological Procedures Online, 4, 24-31. doi:10.1251/bpo30

Devy, L., Blacher, S., Grignet, C., Bajou, K., Masson, V., Gerard, R. D., Gils, A., Carmeliet, G., Carmeliet, P., Declerck, P. J., Noël, A., & Foidart, J.-M. (February 2002). The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB Journal, 16 (2), 147-54. doi:10.1096/fj.01-0552com

Grignet, C., Hajitou, A., Noël, A., & Foidart, J.-M. (2002). Attempt to enhance the suicide gene therapy agaisnt breast cancer cells by using connexin 43 gene. Acta Clinica Belgica, 57 (2), 99.

Hajitou, A., Grignet, C., Devy, L., Berndt, S., Blacher, S., Deroanne, C., Bajou, K., Fong, T., Chiang, Y. W., Foidart, J.-M., & Noël, A. (2002). The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB Journal, 16, 1802-1804. doi:10.1096/fj.02-0109fje

Hajitou, A., Sounni, N. E., Devy, L., Grignet, C., Lewalle, J.-M., Li, H., Deroanne, C., Lu, H., Colige, A., Nusgens, B., Frankenne, F., Maron, A., Yeh, P., Perricaudet, M., Chang, Y., Soria, C., Calberg-Bacq, C.-M., Foidart, J.-M., & Noël, A. (15 April 2001). Down-Regulation of Vascular Endothelial Growth Factor by Tissue Inhibitor of Metalloproteinase-2: Effect on in Vivo Mammary Tumor Growth and Angiogenesis. Cancer Research, 61 (8), 3450-7.

Grignet, C., Cool, V., Baudson, N., Degrève, B., Balzarini, J., De Leval, L., Debrus, S., Velu, T., & Calberg-Bacq, C.-M. (2000). Comparative in vitro and in vivo cytotoxic activity of (E)-5-(2-bromovinyl)-2’-deoxyuridine (BVDU) and its arabinosyl derivative,(E)-5-(2-bromovinyl)-1-b-D-arabinofuranosyluracil (BVaraU), against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinase. Cancer Gene Therapy, 7, 215-223. doi:10.1038/sj.cgt.7700108

Grignet, C., Cool, V., Baudson, N., Velu, T., & Calberg-Bacq, C.-M. (2000). The role of cellular and prodrug-associated factors in the bystander effect induced by the Varicella zoster and the Herpes simplex virus thymidine kinases in suicide gene therapy. Cancer Gene Therapy, 7, 1456-1468. doi:10.1038/sj.cgt.7700250

Grignet, C., Cool, V., Baudson, N., Velu, T., Rentier, B., & Calberg-Bacq, C.-M. (1999). Factors involved in the bystander effect induced by Varicella zoster and Herpes simplex viral thymidine kinase suicide gene therapy. Journal of Gene Medicine, 1, 46.

Grignet, C., & Calberg-Bacq, C.-M. (1997). Potential of Varicella zoster virus thymidine kinase as a suicide gene in breast cancer cells. Gene Therapy, 4, 560-569. doi:10.1038/sj.gt.3300435

Grignet, C., & Calberg-Bacq, C.-M. (1995). A dicistronic vector carrying Varicella zoster virus thymidine kinase confers BVDU sensitivity to breast cancer cells in vitro and in vivo. Cancer Gene Therapy, 2, 246.